Amorphous formulation development - advantages and drawbacks

Karin Kogermann, Peep Veski, Jukka Rantanen, Kaisa Naelapaa

Original language	English
Journal	European Journal of Pharmaceutical Sciences
Volume	44
Issue number	supplement 1
Pages (from-to)	22-23
Number of pages	2
ISSN	0928-0987
DOIs	https://doi.org/10.1016/j.ejps.2011.08.002
Publication status	Published - 24 Sept 2011

Access to Document

4th BBBB-Bled international Conference on Pharmaceutical Sciences
Kaisa Naelapaa (Speaker)
1 Oct 2011
Activity: Talk or presentation types › Lecture and oral contribution

@inproceedings{1ceb69d2f6c24b53859b8391e228bf05,

title = "Amorphous formulation development - advantages and drawbacks",

author = "Karin Kogermann and Peep Veski and Jukka Rantanen and Kaisa Naelapaa",

note = "doi:10.1016/j.ejps.2011.08.002",

year = "2011",

month = sep,

day = "24",

doi = "10.1016/j.ejps.2011.08.002",

language = "English",

volume = "44",

pages = "22--23",

journal = "Norvegica Pharmaceutica Acta",

issn = "0928-0987",

publisher = "Elsevier",

number = "supplement 1",

}

TY - GEN

T1 - Amorphous formulation development - advantages and drawbacks

AU - Kogermann, Karin

AU - Veski, Peep

AU - Rantanen, Jukka

AU - Naelapaa, Kaisa

N1 - doi:10.1016/j.ejps.2011.08.002

PY - 2011/9/24

Y1 - 2011/9/24

U2 - 10.1016/j.ejps.2011.08.002

DO - 10.1016/j.ejps.2011.08.002

M3 - Conference article

SN - 0928-0987

VL - 44

SP - 22

EP - 23

JO - Norvegica Pharmaceutica Acta

JF - Norvegica Pharmaceutica Acta

IS - supplement 1

ER -